GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

compound 5 [PMID: 40393772]   Click here for help

GtoPdb Ligand ID: 13917

Compound class: Synthetic organic
Comment: This is a small molecule selective estrogen receptor α (ERα) degrader (SERD) that was designed for potential to target breast cancer metastases in the brain [2]. Structurally it is a derivative of Zentalis Pharmaceuticals' lead candidate SERD ZN-c5 (in phase 1/2 development for primary breast cancer). Preclinical analyses show that this derivative can cross the blood-brain barrier and is orally bioavailable. It is one of the ER modulators that are claimed in a patent issued to Recurium Ip Holdings [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 30.54
Molecular weight 494.6
XLogP 3.56
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H]1CC2=C([C@@H](C3=C(C=C(C=C3F)NC4CN(CCCF)C4)F)N1C56CC(C5)C6)NC7=C2C=CC=C7
Isomeric SMILES C[C@H]1N(C23CC(C2)C3)[C@H](C4=C(F)C=C(NC5CN(CCCF)C5)C=C4F)C6=C(C1)C7=CC=CC=C7N6
InChI InChI=1S/C29H33F3N4/c1-17-9-22-21-5-2-3-6-25(21)34-27(22)28(36(17)29-12-18(13-29)14-29)26-23(31)10-19(11-24(26)32)33-20-15-35(16-20)8-4-7-30/h2-3,5-6,10-11,17-18,20,28,33-34H,4,7-9,12-16H2,1H3/t17-,18?,28-,29?/m1/s1
InChI Key MOYJTIZSTKNDGD-OEVYRDLRSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Zhang G, Huang PQ, Bunker KD, Hedge SG. (2022)
Estrogen receptor modulators.
Patent number: WO2022140744A1. Assignee: Recurium Ip Holdings, Llc. Priority date: 17/12/2021. Publication date: 30/06/2022.
2. Zhang G, Huang PQ, Bunker KD, Hegde SG, Ma J, Lee CC, Samatar AA, Unni A, Al-Amin M, Kakarla R. (2025)
Discovery of an Orally Bioavailable and Brain Penetrant Selective Estrogen Receptor Degrader.
J Med Chem, [Epub ahead of print]. [PMID:40393772]